Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
KPV vs TB-500
An educational, source-based comparison of KPV and TB-500 — how each peptide works, what it's researched for, and what to know before going deeper.
The C-terminal tripeptide (Lys-Pro-Val) of α-MSH. Research suggests anti-inflammatory effects via melanocortin pathways and intracellular NF-κB modulation — without the pigmentation effects of full-length α-MSH.
- Inflammatory bowel disease models
- Atopic dermatitis (topical research)
- Mast cell stabilization
- • Not FDA-approved.
- • Most evidence is preclinical.
Synthetic fragment of Thymosin Beta-4 studied for tissue and vascular repair.
A synthetic peptide fragment of Thymosin Beta-4 (Tβ4). Research suggests it upregulates actin, promotes cell migration, angiogenesis, and modulates inflammation — supporting repair in muscle, tendon, cardiac, and corneal tissue models.
- Muscle and tendon repair
- Cardiac tissue recovery (preclinical)
- Corneal and dermal wound healing
- Hair follicle stem cell activation
- • Not FDA-approved; banned by WADA.
- • Most evidence is preclinical.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| KPV | KPV reduces colonic inflammation in IBD models | Gastroenterology | 2009 | Oral KPV nanoparticles reduced inflammatory markers in mouse colitis. |
| TB-500 | Thymosin beta-4: a multi-functional regenerative peptide | Expert Opinion on Biological Therapy | 2015 | Review of Tβ4's roles in repair, angiogenesis, and anti-inflammation. |
Side-effect & safety grid
- Not FDA-approved.
- Most evidence is preclinical.
- Not FDA-approved; banned by WADA.
- Most evidence is preclinical.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
KPV vs TB-500 — Key differences
- Class: KPV is classified as Gastrointestinal · Anti-inflammatory, while TB-500 is Tissue Repair · Vascular.
- Primary research focus: KPV — inflammatory bowel disease models; TB-500 — muscle and tendon repair.
- Tag: Gut · Anti-inflammatory vs Recovery.
TB-500 Research Protocol Table
Structured summary of dosing, routes, and durations as described in published research and FDA labels. Educational reference only — not dosing guidance.
| Context | Population | Route | Dose | Duration | Notes |
|---|---|---|---|---|---|
| Tissue and wound recovery (preclinical) | Rodent and large-animal models | Subcutaneous or intramuscular | Equivalent of ~2 mg/kg in some animal models | Single doses to multi-week courses across studies | Cited in preclinical recovery and angiogenesis literature. |
| Cardiac and dermal recovery research (early human work) | Small early-phase human studies of thymosin beta-4 | Topical (dermal ulcers) or IV (cardiac research) | Topical formulations 0.01–0.1% in ulcer studies | Several weeks in dermal-ulcer trials | Early-phase research only; not an FDA-approved drug. |
| Anecdotal injectable use (off-label) | Adults, mixed; off-label | Subcutaneous | Commonly cited 2.0–2.5 mg, 1–2× per week in non-clinical reports | 4–6 week 'loading' phases described in user reports | Banned by WADA in athletes; not a validated clinical protocol. |
TB-500 Research — Female vs Male Studies
How published TB-500 research breaks down by sex, including which populations were studied and what trial data exist.
Female research
Published TB-500 / thymosin beta-4 research includes both sexes in dermal-ulcer and cardiac pilot studies, but female-specific endpoints are not isolated.
- Mixed-sex early-phase human dermal-ulcer studies
- • Pregnancy and lactation data are not established.
- • No sex-stratified outcomes reported in the cited literature.
Male research
Male-specific clinical data for TB-500 are limited to mixed-sex early-phase studies. Anecdotal recovery use reports skew male but are not controlled research.
- Mixed-sex early-phase human studies
- • No male-only TB-500 RCTs identified in the cited literature.
- • WADA prohibits TB-500 in competitive athletes year-round.
TB-500 — Frequently Asked Questions
Is TB-500 the same as thymosin beta-4?+
TB-500 is the research name for a synthetic fragment closely related to thymosin beta-4 (TB-4), the naturally occurring 43-amino-acid peptide. The two terms are often used interchangeably in research literature, though formulations can differ.
Is TB-500 FDA-approved?+
No. TB-500 is not FDA-approved for any indication. Thymosin beta-4 has been studied in early-phase trials for dermal ulcers and cardiac recovery but is not an approved drug.
Why is TB-500 banned in athletes?+
TB-500 is on the World Anti-Doping Agency (WADA) prohibited list year-round as a non-specified prohibited substance, primarily on the basis of its tissue-recovery and angiogenic effects.